Mirna Therapeutics (“Mirna”) announced today that Sinil Kim M.D. has joined the Company as Vice President of Oncology and Chief Medical Officer. Dr. Kim will be responsible for directing clinical development of MRX34 Mirna’s first cancer product candidate as well as advancing the company’s micro-RNA pipeline. The company recently achieved an industry first when MRX34 became the first micro-RNA product to enter a clinical trial in cancer.
“Dr. Kim joins Mirna at an exciting time in our company’s growth as we have just successfully initiated our MRX34 Phase I trial and are looking forward to further growth and maturation of our proprietary micro-RNA discovery platform and preclinical pipeline” said Paul Lammers M.D. President and Chief Executive Officer of Mirna. “The depth and breadth of Sinil’s clinical and regulatory expertise in oncology as well as his reputation as a respected industry executive responsible for successfully developing multiple marketed oncology products will be of significant value to our clinical team as we work together to strengthen our leadership in the development of miRNA-based therapeutics as a promising new class of anticancer agents.”
“The field of micro-RNA based therapeutics has expanded exponentially over the past few years and shows great promise in the fight against cancer” said Dr. Kim. “I am excited to join the Mirna team and look forward to advancing MRX34 the first tumor suppressor miRNA to reach the clinic through the development process as a critically needed potentially new approach to treat cancer.”
Prior to joining Mirna Therapeutics Dr. Kim was most recently a Senior Director at Pfizer Inc. in San Diego CA where he served as the Global Clinical Lead for Inlyta® (axitinib) and Torisel® (temsirolimus) programs. Previously Dr. Kim served as Director of Clinical Oncology at Bristol-Myers Squibb Company where he worked on the clinical development of Erbitux® (cetuximab). Dr. Kim was co-founder of DepoTech in San Diego CA where he invented several liposomal drug products including DepoCyt® (cytarabine liposome injection) DepoDur® (morphine sulfate extended-release liposome injection) and Exparel® (bupivacaine liposome injectable suspension). A board certified medical oncologist Dr. Kim obtained both his Bachelor of Science and medical degrees from the University of Washington in Seattle. His residency in internal medicine and post-doctoral fellowship in hematology/oncology were served respectively at the University of California Irvine and the University of California San Diego.
About Mirna Therapeutics
Mirna Therapeutics Inc. (Mirna) is a biotechnology company focused on the development and commercialization of miRNA therapeutics. The Company has a foundational intellectual property portfolio on the therapeutic use of miRNAs developed by its own scientists as well as in-licensed from other institutions. Mirna’s IP portfolio contains more than 300 miRNAs with applications in oncology and other diseases. Oncology-directed miRNAs include those that are key tumor suppressors in cancer such as miR-34 and let-7 which have been shown to block tumor growth in a number of different preclinical animal studies. The Company founded in 2007 and located in Austin Texas has received significant funding from Sofinnova Ventures New Enterprise Associates Pfizer Venture Investments and other private investors as well as the State of Texas both through the State’s Emerging Technology Fund and from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information visit www.mirnarx.com.Business Wire
Last updated on: 04/06/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.